Cabaletta Bio, Inc.
NASDAQ:CABABiotechnology
+$0.04 today
- Market cap
- $220.03M
- Beta
- 3.23
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.57
Volume 5.46M
Average 3.33M
CABA Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Cabaletta Bio, Inc.NASDAQ: CABA
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation grows in line with its trailing trend
Q1 FY2026 stock-based compensation of $5.26M rose 1.8% year over year, ahead of the +1.0% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 23.4% from the prior quarter. Over 3 fiscal years it compounded at +44.8% a year.
Context
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +1.8% holds above the trailing-twelve-month pace of +1.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 20.94M USD
- Year-over-year change
- +7.6%
- 4-year CAGR
- +37.8%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 20.94M | +7.6% |
| FY2024 | 2024-12-31 | 19.47M | +71.6% |
| FY2023 | 2023-12-31 | 11.34M | +64.5% |
| FY2022 | 2022-12-31 | 6.9M | +18.8% |
| FY2021 | 2021-12-31 | 5.8M | — |
Stock-Based Compensation vs competitors
How CABA compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +1.0% is the 5th highest of 11, against a peer median of -20.1%.
- Over three fiscal years its annual growth of +44.8% compares with a peer median of +4.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $3.98B USD | +32410.1% | +56.9% | — | |
| LTM Mar 2026 | $35.81M USD | +19.3% | — | 115500.0% | |
| LTM Mar 2026 | $33.74M USD | -35.1% | -23.4% | — | |
| LTM Mar 2026 | $21.03M USD | +1.0% | +44.8% | — | |
| LTM Mar 2026 | $17.5M USD | -62.1% | -23.7% | — | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $11.19M USD | -19.1% | +89.6% | — |
| LTM Mar 2026 | $11.09M USD | +34.6% | +121.4% | — | |
| LTM Mar 2026 | $10.44M USD | +45.6% | +16.4% | 517.7% | |
| LTM Mar 2026 | $9.12M USD | -45.7% | -30.1% | 23.6% | |
| LTM Mar 2026 | €2.03M EUR | -21.0% | — | 15.1% | |
| FY2025 | A$1.16M AUD | -35.2% | -7.8% | 23.1% | |
| Peer median (excluding CABA) | — | -20.1% | +4.3% | 23.6% | |
Competitors are the stored peer set for CABA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (46.29M) | (52.98M) | (67.68M) | (115.86M) | (167.86M) |
| Depreciation & Amortization | 733K | 1.18M | 1.43M | 1.71M | 1.65M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.8M | 6.9M | 11.34M | 19.47M | 20.94M |
| Change in Working Capital | 5.58M | (4.3M) | 101K | 1.61M | (379K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 975K | (28K) | 1.68M | 1.01M | 1.55M |
| Other Working Capital | 4.61M | (4.27M) | (1.57M) | 600K | (1.93M) |
| Other Non-Cash Items | 62K | 2.82M | 1.26M | 4.86M | 14.57M |
| Operating Cash Flow | (34.11M) | (46.38M) | (53.55M) | (88.22M) | (131.08M) |
| Capital Expenditures | (1.17M) | (2.45M) | (687K) | (2.21M) | (1.23M) |
| Acquisitions (Net) | 0 | 24.76K | 0 | 0 | 0 |
| Purchases of Investments | 0 | (49.76M) | (84.26M) | 0 | (99.04M) |
| Sales of Investments | 7.17M | 25M | 62.5M | 49.5M | 50M |
| Other Investing Activities | 0 | (24.76K) | 0 | 0 | 0 |
| Investing Cash Flow | 6M | (27.22M) | (22.45M) | 47.29M | (50.27M) |
| Debt Repayment | 0 | 0 | 0 | (897K) | (6.26M) |
| Common Stock Issued | 48.25M | 32.86M | 185.2M | 10.88M | 106.61M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 650K | 127K | 2.43M | 1.7M | 0 |
| Financing Cash Flow | 48.9M | 32.98M | 187.63M | 11.68M | 100.35M |
| Effect of Forex Changes | 0 | 0 | 0 | (20K) | 19K |
| Net Change in Cash | 20.79M | (40.62M) | 111.63M | (29.28M) | (80.98M) |
| Free Cash Flow | (35.28M) | (48.83M) | (54.24M) | (90.43M) | (132.31M) |
Cabaletta Bio, Inc.
NASDAQ:CABA
Intrinsic Alpha fair value
Locked
Current Price
$1.02
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.